Key factors
sym | PRNB |
exch | US |
MCap | 3.325B |
Beta | 0.859 |
EPS | -0.09 |
Div date | 0000-00-00 |
Yesterday
sym | PRNB |
exch | US |
50 Day MA | 100.10 |
200 Day MA | 74.18 |
52 Week High | 101.89 |
52 Week Low | 28.3 |
Target Price | 86.0 |
Market Cap Mln | 3325.28 |
Share statistics
Shares Outstanding | 33.23M |
Shares Float | 26.61M |
Percent Institutions | 100.78 |
PercentInsiders | 1.39 |
SharesShort | 1581.54K |
Short Ratio | 0.5 |
Shares Short Prior Month | 2004.25K |
Short Percent | 6.480 |
Short Percent Float | 6.480 |
Short Percent Outstanding | 5.000 |
Income
Revenue TTM | 50.0M |
Revenue Per Share TTM | 1.647 |
Quarterly Revenue Growth YOY | 66.69 |
Gross Profit TTM | 35.16M |
EBITDA | 6898.0K |
Diluted Eps TTM | -2.27 |
Quarterly Earnings Growth YOY | 10.70 |
earning
Operating Margin TTM | -1.48 |
EPS Estimate Current Year | -3.65 |
EPS Estimate Next Year | -5.22 |
Earnings Share | -0.09 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Revenue | 60.40 |
Book Value /share | 10.59 |
Price Book MRQ | 9.452 |
Price Sales TTM | 60.66 |
ProfitMargin | -1.37 |
ReturnOnAssetsTTM | -0.16 |
ReturnOnEquityTTM | -0.26 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
CIK | 0001510487 |
Code | PRNB |
CUSIP | 74257L108 |
Employer Id Number | 26-3487603 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2020-10-08 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 124.0 |
IPODate | 2018 |
International Domestic | Domestic |
MostRecent Quarter | 2020-06-30 |
Contact
Name | Principia Biopharma Inc |
Address | 220 East Grand Avenue, South San Francisco, CA, United States, 94080 |
Country Name | USA |
Phone | 650 416 7700 |
Web URL | www.principiabio.com |
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-medicated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California. As of September 25, 2020, Principia Biopharma Inc. operates as a subsidiary of Sanofi.